Canakinumab for the treatment of gout
Gout is the one of the most common forms of inflammatory arthritis in adults. As the incidence and prevalence of gout are increasing and many patients cannot tolerate or have contraindications to standard treatments, there is a need for new, more effective therapeutic agents. IL-1ββ is a proinflamm...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical rheumatology 2011-12, Vol.6 (6), p.605-615 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 615 |
|---|---|
| container_issue | 6 |
| container_start_page | 605 |
| container_title | International journal of clinical rheumatology |
| container_volume | 6 |
| creator | Pazár Maldonado, Borbála So, Alexander |
| description | Gout is the one of the most common forms of inflammatory arthritis in adults. As the incidence and prevalence of gout are increasing and many patients cannot tolerate or have contraindications to standard treatments, there is a need for new, more effective therapeutic agents. IL-1ββ is a proinflammatory cytokine that plays a pivotal role in the pathogenesis of gouty arthritis. Several inhibitors of IL-1 have been elaborated to date. Canakinumab is a fully human monoclonal antibody to IL-1ββ developed by Novartis. According to recently published results of clinical trials, canakinumab may provide a safe and effective alternative treatment option for gout flares for patients in whom standard therapies are not advised. |
| doi_str_mv | 10.2217/ijr.11.57 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_905685563</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A273648555</galeid><sourcerecordid>A273648555</sourcerecordid><originalsourceid>FETCH-LOGICAL-c238t-e21c19b6c65f650ea36469a7f6c3606390a169bfc416bcaaa9c0ea71b3dfeb233</originalsourceid><addsrcrecordid>eNptkE9LAzEQxYMoWGoPfoNF8eBh10yySTbHUvwHBS96Dtk0qVu7m5pkD357U1YEwZnDDMPvzYOH0CXgihAQd90uVAAVEydoBoI1ZU0afPq7C3KOFjHucC4KdSPxDN2s9KA_umHsdVs4H4r0bosUrE69HVLhXbH1Y7pAZ07vo138zDl6e7h_XT2V65fH59VyXRpCm1RaAgZkyw1njjNsNeU1l1o4bijHnEqsgcvWmRp4a7TW0mRIQEs3zraE0jm6mv4egv8cbUxq58cwZEslMeMNY_wIXU_QVu-t6gbnU9Cm76JRSyKyZcZYpqp_qNwb23fGD9Z1-f5HcDsJTPAxBuvUIXS9Dl8KsDrGq3K8CkAxQb8BOHFqGA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>905685563</pqid></control><display><type>article</type><title>Canakinumab for the treatment of gout</title><source>Alma/SFX Local Collection</source><creator>Pazár Maldonado, Borbála ; So, Alexander</creator><creatorcontrib>Pazár Maldonado, Borbála ; So, Alexander</creatorcontrib><description>Gout is the one of the most common forms of inflammatory arthritis in adults. As the incidence and prevalence of gout are increasing and many patients cannot tolerate or have contraindications to standard treatments, there is a need for new, more effective therapeutic agents. IL-1ββ is a proinflammatory cytokine that plays a pivotal role in the pathogenesis of gouty arthritis. Several inhibitors of IL-1 have been elaborated to date. Canakinumab is a fully human monoclonal antibody to IL-1ββ developed by Novartis. According to recently published results of clinical trials, canakinumab may provide a safe and effective alternative treatment option for gout flares for patients in whom standard therapies are not advised.</description><identifier>ISSN: 1758-4272</identifier><identifier>EISSN: 1758-4280</identifier><identifier>DOI: 10.2217/ijr.11.57</identifier><language>eng</language><publisher>London: Future Medicine Ltd</publisher><subject>Cytokines ; Drug therapy ; Gout ; Health aspects ; Monoclonal antibodies</subject><ispartof>International journal of clinical rheumatology, 2011-12, Vol.6 (6), p.605-615</ispartof><rights>COPYRIGHT 2011 Future Medicine Ltd.</rights><rights>2011 Future Medicine Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c238t-e21c19b6c65f650ea36469a7f6c3606390a169bfc416bcaaa9c0ea71b3dfeb233</citedby><cites>FETCH-LOGICAL-c238t-e21c19b6c65f650ea36469a7f6c3606390a169bfc416bcaaa9c0ea71b3dfeb233</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Pazár Maldonado, Borbála</creatorcontrib><creatorcontrib>So, Alexander</creatorcontrib><title>Canakinumab for the treatment of gout</title><title>International journal of clinical rheumatology</title><description>Gout is the one of the most common forms of inflammatory arthritis in adults. As the incidence and prevalence of gout are increasing and many patients cannot tolerate or have contraindications to standard treatments, there is a need for new, more effective therapeutic agents. IL-1ββ is a proinflammatory cytokine that plays a pivotal role in the pathogenesis of gouty arthritis. Several inhibitors of IL-1 have been elaborated to date. Canakinumab is a fully human monoclonal antibody to IL-1ββ developed by Novartis. According to recently published results of clinical trials, canakinumab may provide a safe and effective alternative treatment option for gout flares for patients in whom standard therapies are not advised.</description><subject>Cytokines</subject><subject>Drug therapy</subject><subject>Gout</subject><subject>Health aspects</subject><subject>Monoclonal antibodies</subject><issn>1758-4272</issn><issn>1758-4280</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkE9LAzEQxYMoWGoPfoNF8eBh10yySTbHUvwHBS96Dtk0qVu7m5pkD357U1YEwZnDDMPvzYOH0CXgihAQd90uVAAVEydoBoI1ZU0afPq7C3KOFjHucC4KdSPxDN2s9KA_umHsdVs4H4r0bosUrE69HVLhXbH1Y7pAZ07vo138zDl6e7h_XT2V65fH59VyXRpCm1RaAgZkyw1njjNsNeU1l1o4bijHnEqsgcvWmRp4a7TW0mRIQEs3zraE0jm6mv4egv8cbUxq58cwZEslMeMNY_wIXU_QVu-t6gbnU9Cm76JRSyKyZcZYpqp_qNwb23fGD9Z1-f5HcDsJTPAxBuvUIXS9Dl8KsDrGq3K8CkAxQb8BOHFqGA</recordid><startdate>20111201</startdate><enddate>20111201</enddate><creator>Pazár Maldonado, Borbála</creator><creator>So, Alexander</creator><general>Future Medicine Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20111201</creationdate><title>Canakinumab for the treatment of gout</title><author>Pazár Maldonado, Borbála ; So, Alexander</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c238t-e21c19b6c65f650ea36469a7f6c3606390a169bfc416bcaaa9c0ea71b3dfeb233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Cytokines</topic><topic>Drug therapy</topic><topic>Gout</topic><topic>Health aspects</topic><topic>Monoclonal antibodies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pazár Maldonado, Borbála</creatorcontrib><creatorcontrib>So, Alexander</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>International journal of clinical rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pazár Maldonado, Borbála</au><au>So, Alexander</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Canakinumab for the treatment of gout</atitle><jtitle>International journal of clinical rheumatology</jtitle><date>2011-12-01</date><risdate>2011</risdate><volume>6</volume><issue>6</issue><spage>605</spage><epage>615</epage><pages>605-615</pages><issn>1758-4272</issn><eissn>1758-4280</eissn><abstract>Gout is the one of the most common forms of inflammatory arthritis in adults. As the incidence and prevalence of gout are increasing and many patients cannot tolerate or have contraindications to standard treatments, there is a need for new, more effective therapeutic agents. IL-1ββ is a proinflammatory cytokine that plays a pivotal role in the pathogenesis of gouty arthritis. Several inhibitors of IL-1 have been elaborated to date. Canakinumab is a fully human monoclonal antibody to IL-1ββ developed by Novartis. According to recently published results of clinical trials, canakinumab may provide a safe and effective alternative treatment option for gout flares for patients in whom standard therapies are not advised.</abstract><cop>London</cop><pub>Future Medicine Ltd</pub><doi>10.2217/ijr.11.57</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1758-4272 |
| ispartof | International journal of clinical rheumatology, 2011-12, Vol.6 (6), p.605-615 |
| issn | 1758-4272 1758-4280 |
| language | eng |
| recordid | cdi_proquest_journals_905685563 |
| source | Alma/SFX Local Collection |
| subjects | Cytokines Drug therapy Gout Health aspects Monoclonal antibodies |
| title | Canakinumab for the treatment of gout |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T11%3A27%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Canakinumab%20for%20the%20treatment%20of%20gout&rft.jtitle=International%20journal%20of%20clinical%20rheumatology&rft.au=Paz%C3%A1r%20Maldonado,%20Borb%C3%A1la&rft.date=2011-12-01&rft.volume=6&rft.issue=6&rft.spage=605&rft.epage=615&rft.pages=605-615&rft.issn=1758-4272&rft.eissn=1758-4280&rft_id=info:doi/10.2217/ijr.11.57&rft_dat=%3Cgale_proqu%3EA273648555%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=905685563&rft_id=info:pmid/&rft_galeid=A273648555&rfr_iscdi=true |